Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain

Medtronic plc, a global leader in healthcare technology, has finalized its acquisition of SPR Therapeutics, Inc. for $650 million. The deal, announced on July 16, 2026, aims to enhance Medtronic's pain therapy portfolio by integrating SPR's innovative SPRINT® peripheral nerve stimulation (PNS) technology. This acquisition is positioned to broaden patient access to effective pain management solutions, particularly for those suffering from chronic and acute pain.

SPR Therapeutics is recognized for its pioneering work in short-term, percutaneous PNS therapies, which provide a non-opioid and non-surgical option for pain relief. The SPRINT® PNS System, which is FDA-cleared, offers a minimally invasive treatment approach that delivers mild electrical stimulation to targeted peripheral nerves. This therapy is designed to alleviate pain for up to 60 days without the need for a permanent implant. Clinical studies have demonstrated that approximately 60% of patients experience significant pain relief, with an average reduction in pain intensity of 76% among responders. Given that chronic pain affects nearly 50 million adults in the U.S., the integration of this technology into Medtronic's offerings is strategically significant.

The acquisition aligns with Medtronic's broader strategy to enhance its leadership in the healthcare technology sector, particularly in pain management. By incorporating SPR's SPRINT® technology, Medtronic not only expands its existing pain therapy portfolio but also reinforces its commitment to providing innovative, patient-centric solutions. The deal is expected to be minimally dilutive to Medtronic's adjusted earnings per share in fiscal year 2027 and neutral to accretive thereafter, indicating a well-calculated investment aimed at long-term growth.

The healthcare technology sector is witnessing a growing demand for non-opioid pain management solutions, driven by increasing awareness of opioid-related risks and a shift towards more holistic approaches to pain treatment. As healthcare providers seek effective alternatives, the integration of SPR's PNS technology into Medtronic's portfolio positions the company favorably within this evolving landscape. The acquisition is likely to enhance Medtronic's competitive edge as it addresses the pressing need for innovative therapies that improve patient outcomes.

In conclusion, Medtronic's acquisition of SPR Therapeutics represents a strategic move to bolster its capabilities in pain management amidst a rapidly changing healthcare environment. By expanding access to advanced, minimally invasive therapies, Medtronic is poised to meet the growing demand for effective pain relief solutions. This acquisition not only strengthens Medtronic's market position but also reflects broader trends in the healthcare technology sector towards innovative, patient-focused care solutions.